QALY

Market Access

Beyond the Bill: how do we make medicines affordable without...

Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.

Market Access

NICE contribution to the cost per QALY threshold debate?

Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency and highlights the opportunity for stakeholders to build their c

News

ICER methods could be illegal in US, claims US think tank

Views & Analysis

Collaboration can ensure access to life-changing innovation

As a pioneering risk sharing scheme has shown, new medications can be the catalyst for a whole new care infrastructure.

Partner Content

Orphan medicines, advances, access and affordability

LONDON, UNITED KINGDOM, April 19th 2017:

Beyond the Bill: how do we make medicines affordable without...

NICE contribution to the cost per QALY threshold debate?

ICER methods could be illegal in US, claims US think tank

Collaboration can ensure access to life-changing innovation

Orphan medicines, advances, access and affordability

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

QALY

Editor's Picks